首页 > Avidity > Avidity/BIP300 - BIP-300 - positive control plasmid for induction/1/BIP300

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

Avidity/BIP300 - BIP-300 - positive control plasmid for induction/1/BIP300

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

BIP300

品牌：

Avidity

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Product InformationThe BIP-300 plasmid allows you to compare your pAN or pAC AviTagTM fusion gene"s protein expression against a confirmed AviTagTM fusion product under the same growth and induction conditions. When transformed into the same E. coli host strain as your own pAN or pAC AviTagTM fusion plasmid construct, and induced in parallel, the BIP-300 Positive Control Plasmid will provide a measure by which to compare your transformation efficiency, growth and antibiotic maintenance conditions, and induction of your plasmid"s gene-fusion construct. The BIP-300 construct consists of a modified β-galactosidase gene (8 amino acids were deleted from its N-terminus) cloned into Avidity"s pAN5 AviTagTM fusion vector at the Multiple Cloning Site. The resulting AviTagTM-protein fusion (AviTag-β-gal), as are all the pAN and pAC fusion products, is under the tight control of the Trc promoter system and expressed upon IPTG induction. The plasmid is maintained with ampicillin. An example induction protocol is given under Protocols. This protocol uses the Avidity AVB101 E. coli strain containing the BirA over-expressing pACYC-184 plasmid construct (pBirAcm) as the host strain. It is initially requires chloramphenicol for maintenance in addition to the ampicillin required to maintain the pAN or pAC plasmid construct. If you are using a different host strain please adjust the protocol accordingly.Supplied as 1 vial of Positive Control Plasmid DNA; 2µg at 1mg/mL in nuclease-free water (2µL). Store at -20°C.

亲和生物科学公司是一家私营生物技术公司，是一家开创抗体寡核苷酸结合(AOC)的公司。™)AOCs结合了单克隆抗体的组织选择性和基于寡核苷酸的治疗方法的精确性，以克服寡核苷酸传递的障碍和疾病的目标遗传驱动因素。它们的AOC平台，演示了疾病相关RNA在细胞类型和组织中的调节，包括肌肉、心脏、肝脏、肿瘤和免疫细胞。专有的平台技术可以在单一抗体支架上传递多种治疗性寡核苷酸。AOCs具有类似于抗体的药物性质，并允许将寡核苷酸有效载荷传递到其他运载平台所不提供的非肝组织。AOC也有其独特之处，因为可以处理不可药物的目标。

它们正在推进一系列的治疗计划，重点是罕见的肌肉疾病和其他严重疾病。主要项目是开发治疗杜氏肌营养不良和肌营养不良患者的治疗方法。还与制药合作伙伴合作开展项目。并得到了经验丰富的团队和受人尊敬的生命科学投资者的支持。